Fatih Mehmet Akif ÖZDEMİR, Nesrin CEYLAN, Halil ÇELİK, Damla YILDIZ, Ayşe AKSOY, Deniz YÜKSEL

Senkopla Başvuran Bir Guillain-Barre Sendromu: Olgu Sunumu

Guillain Barre Sendromu (GBS), sıklıkla simetrik güçsüzlük ve arefleksi ile karakterize akut inflamatuar polinöropatidir. Geçirilmiş bakteriyel veya viral enfeksiyonların tetiklediği otoimmün bir hastalık olduğu kabul edilmektedir. Miller Fisher sendromu, GBS'nin en sık görülen varyantlarından biri olup, arefleksi, ataksi ve oftalmoparezi ile seyretmesi özelliğidir. Çocukluk çağı GBS'de mortalite %1-2 oranındadır ve genellikle solunum yetersizliğine bağlı olarak gelişir. Burada parvovirus B19 enfeksiyonu sonrası gelişen Guillain-Barre Sendromlu (GBS) bir olgu başvuru semptomunun otonom tutuluma bağlı gelişmiş olabileceği düşünülen senkop olması nedeniyle gözden geçirildi.

Anahtar Kelimeler:

Guillian-Barre Sendromu, Miller Fisher sendromu, Senkop

A Guillain-Barre Syndrome Presenting with Syncope

Guillain Barre Syndrome (GBS) is an acute inflammatory polyneuropathy, often characterized by symmetrical weakness and areflexia. It is considered to be an autoimmune disease triggered by previous bacterial or viral infections. Miller Fisher’s syndrome is one of the most common variants of GBS, and it is characterized by trauma with areflexia, ataxia, and ophthalmoparesis. Mortality is 1-2% in childhood GBS and generally develops due to respiratory failure. Here, a case with Guillain-Barre Syndrome (GBS) developed after parvovirus B19 infection was reviewed because the symptom of the application was syncope, which is thought to be developed due to autonomic involvement.

Keywords:

Guillian-Barre Syndrome, Miller Fisher’s syndrome, Syncope,

PDF

___

1. Asbury A, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre Syndrome. Ann Neurol 1990; 27: 21-4.
2. Ropper AH. The Guillain Barre syndrome. N Engl J Med 1992; 23: 1130-6.
3. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32: 150- 63
4. Rantala H, Uhari M, Niemela M. Occurrence, clinical manifestations, and prognosis of Guillain-Barre Syndrome, Arch Dis Child 1991; 66: 706.
5. Menkes HJ: Immunologically mediated demyelinating diseases of the peripheral nervous system, Guillain-Barre Syndrome. In: Menkes HJ, Sarnat BH eds. Textbook of Child Neurology. Philadelphia: Lippincott Williams and Wilkins 2000: 658-65.
6. Kuwabara S, Mori M, Ogawara K et al. Indicators of rapid clinical recovery in Guillain Barre syndrome. J Neurol Neurosurg Psychiatry 2001; 70: 560-2.
7. Delanoe C, Sebire G, Landrieu P, Huault G, Metral S. Acute inflammatory demyelinating polyradiculopathy in children: Clinical and electrodiagnostic studies. Ann Neurol 1998; 44: 350-6.
8. Visser LH, van der Meche FG, Meulstee J et al. Cytomegalovirus infection and Guillain- Barre syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain- Barre Study Group. Neurology 1996; 47: 668-73.
9. Yuki N, Ang CW, Koga M, et al. Clinical features and response to treatment in Guillain- Barre Syndrome associated with antibodies to GM1b ganglioside Ann Neurol 2000; 47: 314-21.
10. Italian Guillain-Barre Study Group. The prognosis and main prognostic indicators of Guillain Barre syndrome. A multicentre prospective study of 297 patients. Brain 1996; 119: 2053-61.
11. Bradshaw DY, Jones HR Jr. Guillain-Barre syndrome in children: Clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15: 500-6.
12. Moulin DE, Hagen N, Feasby TE, et al. Pain in Guillain-Barre syndrome. Neurology 1997; 48: 328-31.
13. Larsen A, Tobias JD. Guillain-Barre syndrome presenting with symptoms of upper airway obstruction. Pediatr Emerg Care 1994; 10: 347-8.
14. Briscoe DM, Mc Menamin JB, O'Donohoe NV. Prognosis in Guillain-Barre syndrome Arch Dis Child 1987; 62: 733-5.
15. Jones HR. Childhood Guillain-Barre syndrome: Clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11: 4-12.